(Reuters) – Drugmaker Incyte said on Tuesday its cream to treat a type of skin disease met its main goal of improving skin clarity in patients with atopic dermatitis in a late-stage study.
Atopic dermatitis is a common chronic disease characterized by inflammation of the skin.
The study was testing the ruxolitinib cream in adolescent and adult patients aged 12 years and above.
Reporting by Trisha Roy in Bengaluru; Editing by Amy Caren Daniel
Source: Reuters.com © 2019 Thomson Reuters. All rights reserved. Reuters content is the intellectual property of Thomson Reuters or its third party content providers. Any copying, republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. “Reuters” and the Reuters Logo are trademarks of Thomson Reuters and its affiliated companies.Follow us: